• +1-646-491-9876
    • +91-20-67278686

    Search

    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016

    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016

    • Report Code ID: RW0001499776
    • Category Pharmaceuticals
    • No. of Pages 42
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016', provides in depth analysis on Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted pipeline therapeutics.

    The report provides comprehensive information on the Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
    - The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Overview 6
    Therapeutics Development 7
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Stage of Development 7
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Therapy Area 8
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Indication 9
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Products Glance 10
    Late Stage Products 10
    Early Stage Products 11
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Companies 12
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Universities/Institutes 14
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Therapeutics Assessment 16
    Assessment by Monotherapy/Combination Products 16
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 18
    Assessment by Molecule Type 19
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Companies Involved in Therapeutics Development 21
    AbbVie Inc 21
    Ascentage Pharma Group Corp Ltd 22
    Takeda Pharmaceutical Company Limited 23
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Drug Profiles 24
    ABT-737 - Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    APG-1252 - Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    navitoclax dihydrochloride - Drug Profile 26
    Product Description 26
    Mechanism Of Action 26
    R&D Progress 26
    rottlerin - Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    WEHI-539 - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Dormant Projects 34
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Discontinued Products 38
    Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Featured News & Press Releases 39
    Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539 39
    Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology 39
    May 16, 2005: Abbott Data Published In Nature Reveals A Promising New Approach In Cancer. 40
    Appendix 41
    Methodology 41
    Coverage 41
    Secondary Research 41
    Primary Research 41
    Expert Panel Validation 41
    Contact Us 41
    Disclaimer 42

    List of Tables

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Therapy Area, H2 2016 8
    Number of Products under Development by Indication, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 11
    Number of Products under Development by Companies, H2 2016 12
    Products under Development by Companies, H2 2016 13
    Number of Products under Investigation by Universities/Institutes, H2 2016 14
    Products under Investigation by Universities/Institutes, H2 2016 15
    Assessment by Monotherapy/Combination Products, H2 2016 16
    Number of Products by Stage and Mechanism of Action, H2 2016 17
    Number of Products by Stage and Route of Administration, H2 2016 18
    Number of Products by Stage and Molecule Type, H2 2016 20
    Pipeline by AbbVie Inc, H2 2016 21
    Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 22
    Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 23
    Dormant Projects, H2 2016 34
    Dormant Projects (Contd..1), H2 2016 35
    Dormant Projects (Contd..2), H2 2016 36
    Dormant Projects (Contd..3), H2 2016 37
    Discontinued Products, H2 2016 38

    List of Figures

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Therapy Area, H2 2016 8
    Number of Products under Development by Top 10 Indication, H2 2016 9
    Comparative Analysis by Early Stage Products, H2 2016 11
    Assessment by Monotherapy/Combination Products, H2 2016 16
    Number of Products by Stage and Mechanism of Actions, H2 2016 17
    Number of Products by Molecule Types, H2 2016 19
    Number of Products by Stage and Molecule Type, H2 2016 19
    AbbVie Inc
    Ascentage Pharma Group Corp Ltd
    Takeda Pharmaceutical Company Limited

    Request for Sample

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments